Halozyme Therapeutics (NASDAQ: HALO) announced a global collaboration and license agreement with AbbVie (NYSE: ABBV) to develop and commercialize products ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE